== Microarray screening of 10 antibody-secreting cell (ASC)-probes and 3 matching sera/plasma
== Microarray screening of 10 antibody-secreting cell (ASC)-probes and 3 matching sera/plasma. == 3. a highly specific source of tumor-specific antibodies. Each breast malignancy patient reacts with a different antibody profile which indicates that targeted immunotherapies may need to be personalized for individual patients. Focused microarrays in combination with ASC-probes may be useful in providing immune profiles and identifying tumor antigens of individual cancer patients. Keywords:tumor antigen, immune profile, lymph node, antibody secreting cell, biomarker, microarray, breast malignancy, immunotherapy == 1. Introduction == Immunotherapy has changed the AZD-3965 scenery of cancer treatment for an increasing number of solid tumors and has increased interest in the immunological status of cancer patients [1,2]. An antitumor immune response, generated naturally or through vaccination, is critically dependent on the presence of tumor antigens generated during cancer formation. Tumor antigens expressed on the surface of tumor cells can also provide attractive targets for new and personalized immunotherapy approaches [3,4]. A major effort is therefore being directed towards identifying tumor antigens expressed by individual malignancy patients. Tumor antigens are recognized by both T and B cell receptors, although in different formats (peptide vs. native molecule), and most B cell responses require T cell help for clonal growth and the generation of antibody-secreting cells (ASCs) [5]. The initial interactions between antigen-presenting cells and T and B cells takes place in the lymph nodes draining the target tissues and result in the production of antigen-specific ASCs. Fully differentiated ASCs can secrete thousands of antibody molecules per second [6] and therefore provide a significant biological amplification of molecular changes occurring in cancer cells and a reflection of the tumors antigenic profile. Antibodies produced by ASCs are released into the blood stream, where they are vastly diluted with nonspecific antibodies. The formation of immune complexes can also reduce sensitivity and specificity when serum is used as the antibody source in immunoassays [7,8]. Recent advances in protein microarray-based antibody profiling have in part resolved these issues with reported high sensitivity and reproducibility [9]. Nonetheless, additional improvements may be obtained by selecting a more specific source of antitumor antibodies [4]. It has been known for a long time that regional lymph nodes of breast AZD-3965 tumors are often enlarged, even in the absence of metastatic tumor cells, indicating that an active immune response is taking place [10]. Changes in the general immune profile of breast cancer-draining lymph nodes have also been found to predict recurrence regardless of metastasis status [11]. More recently, tumor-draining lymph nodes of breast cancer patients have been shown to contain increased numbers of germinal centers and immunoglobulin (Ig)G+B cells [12,13] and the clonality and diversity of B cell receptor genes have been correlated with survival and response to immunotherapy in subtypes of breast and ovarian cancer [14]. These findings indicate that AZD-3965 capturing the antibody response of tumor-specific ASCs in the lymph node of individual patients may provide a more specific source of antibodies for identifying tumor antigens and a patients baseline immune status and antigen profile. Previous infectious disease studies have shown that short term culture of lymph node cells results in the release of antibodies in the culture supernatant that reflect the total antigen repertoire of the pathogen present in the target tissue at the time of lymph node collection [15,16]. The culture supernatants, made up of antibodies secreted by in vivo induced ASCs, termed ASC-probes, have been used to identify stage-specific pathogen antigens using standard immune-technological approaches [15,17]. In the present study, we apply this technology to generate ASC-probes from the lymph nodes of breast cancer patients and compare the individual antibody response against breast malignancy cell lines. In addition, we combine Rabbit Polyclonal to p44/42 MAPK the ASC approach.